Do analysts rate DXR or HSCS?

HeartSciences has a consensus target price of $8.00, indicating a potential upside of 75.79%. Given HeartSciences' higher probable upside, analysts plainly believe HeartSciences is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, DXR or HSCS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daxor N/A N/A N/A N/A N/A HeartSciences N/A N/A -$9.14M -$3.22 N/A

Is DXR or HSCS more profitable?

Daxor's return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets Daxor N/A N/A N/A HeartSciences N/A -816.90% -181.97%

Is HSCS or NYXH more profitable?

HeartSciences has a net margin of 0.00% compared to Nyxoah's net margin of -443.16%. Nyxoah's return on equity of -178.90% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -816.90% -181.97% Nyxoah -443.16% -178.90% -81.83%

Does the media refer more to HSCS or NYXH?

In the previous week, HeartSciences and HeartSciences both had 4 articles in the media. HeartSciences' average media sentiment score of 0.97 beat Nyxoah's score of 0.46 indicating that HeartSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartSciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nyxoah 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NNOX or HSCS more profitable?

HeartSciences has a net margin of 0.00% compared to Nano-X Imaging's net margin of -926.05%. Nano-X Imaging's return on equity of -116.93% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets Nano-X Imaging -926.05% -116.93% -100.67% HeartSciences N/A -816.90% -181.97%

HeartSciences (HSCS) Competitors

$4.55 -0.18 (-3.78%)

As of 11:18 AM Eastern

Compare

HSCS vs. DXR, NYXH, OM, COCH, and NNOX

Should you buy HeartSciences stock or one of its competitors? HeartSciences's main competitors and comparable companies include Daxor (DXR), Nyxoah (NYXH), Outset Medical (OM), Envoy Medical (COCH), and Nano-X Imaging (NNOX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does HeartSciences compare to Daxor?

Daxor (NASDAQ:DXR) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Daxor's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
HeartSciences	N/A	-816.90%	-181.97%

Daxor has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, HeartSciences has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market.

HeartSciences has a consensus target price of $8.00, indicating a potential upside of 75.79%. Given HeartSciences' higher probable upside, analysts plainly believe HeartSciences is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

1.3% of Daxor shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 51.5% of Daxor shares are owned by insiders. Comparatively, 4.9% of HeartSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A

In the previous week, HeartSciences had 3 more articles in the media than Daxor. MarketBeat recorded 4 mentions for HeartSciences and 1 mentions for Daxor. Daxor's average media sentiment score of 1.82 beat HeartSciences' score of 0.97 indicating that Daxor is being referred to more favorably in the media.

Company	Overall Sentiment
Daxor	Very Positive
HeartSciences	Positive

Summary

Daxor beats HeartSciences on 5 of the 9 factors compared between the two stocks.

How does HeartSciences compare to Nyxoah?

HeartSciences (NASDAQ:HSCS) and Nyxoah (NASDAQ:NYXH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

HeartSciences has a net margin of 0.00% compared to Nyxoah's net margin of -443.16%. Nyxoah's return on equity of -178.90% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-816.90%	-181.97%
Nyxoah	-443.16%	-178.90%	-81.83%

HeartSciences presently has a consensus target price of $8.00, indicating a potential upside of 75.79%. Nyxoah has a consensus target price of $4.26, indicating a potential upside of 170.60%. Given Nyxoah's stronger consensus rating and higher probable upside, analysts clearly believe Nyxoah is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, HeartSciences and HeartSciences both had 4 articles in the media. HeartSciences' average media sentiment score of 0.97 beat Nyxoah's score of 0.46 indicating that HeartSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartSciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nyxoah	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HeartSciences has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market. Comparatively, Nyxoah has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

17.2% of HeartSciences shares are held by institutional investors. 4.9% of HeartSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

HeartSciences has higher earnings, but lower revenue than Nyxoah. HeartSciences is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A
Nyxoah	$11.33M	5.39	-$101.92M	-$2.52	N/A

Summary

Nyxoah beats HeartSciences on 8 of the 14 factors compared between the two stocks.

How does HeartSciences compare to Outset Medical?

Outset Medical (NASDAQ:OM) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

17.2% of HeartSciences shares are owned by institutional investors. 2.5% of Outset Medical shares are owned by company insiders. Comparatively, 4.9% of HeartSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

HeartSciences has a net margin of 0.00% compared to Outset Medical's net margin of -63.06%. Outset Medical's return on equity of -61.67% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Outset Medical	-63.06%	-61.67%	-28.25%
HeartSciences	N/A	-816.90%	-181.97%

Outset Medical presently has a consensus price target of $10.00, indicating a potential upside of 244.95%. HeartSciences has a consensus price target of $8.00, indicating a potential upside of 75.79%. Given Outset Medical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Outset Medical is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Outset Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Outset Medical has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market. Comparatively, HeartSciences has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market.

HeartSciences has lower revenue, but higher earnings than Outset Medical. HeartSciences is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Outset Medical	$119.48M	0.46	-$81.65M	-$4.09	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A

In the previous week, HeartSciences had 3 more articles in the media than Outset Medical. MarketBeat recorded 4 mentions for HeartSciences and 1 mentions for Outset Medical. Outset Medical's average media sentiment score of 1.79 beat HeartSciences' score of 0.97 indicating that Outset Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Outset Medical	Very Positive
HeartSciences	Positive

Summary

Outset Medical beats HeartSciences on 9 of the 15 factors compared between the two stocks.

How does HeartSciences compare to Envoy Medical?

HeartSciences (NASDAQ:HSCS) and Envoy Medical (NASDAQ:COCH) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, HeartSciences had 3 more articles in the media than Envoy Medical. MarketBeat recorded 4 mentions for HeartSciences and 1 mentions for Envoy Medical. HeartSciences' average media sentiment score of 0.97 beat Envoy Medical's score of 0.89 indicating that HeartSciences is being referred to more favorably in the media.

Company	Overall Sentiment
HeartSciences	Positive
Envoy Medical	Positive

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 8.6% of Envoy Medical shares are held by institutional investors. 4.9% of HeartSciences shares are held by insiders. Comparatively, 7.2% of Envoy Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

HeartSciences has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market. Comparatively, Envoy Medical has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market.

HeartSciences presently has a consensus price target of $8.00, suggesting a potential upside of 75.79%. Envoy Medical has a consensus price target of $2.00, suggesting a potential upside of 185.31%. Given Envoy Medical's higher possible upside, analysts plainly believe Envoy Medical is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartSciences has higher earnings, but lower revenue than Envoy Medical. HeartSciences is trading at a lower price-to-earnings ratio than Envoy Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A
Envoy Medical	$240K	225.46	-$23.76M	-$0.76	N/A

HeartSciences has a net margin of 0.00% compared to Envoy Medical's net margin of -11,304.83%. Envoy Medical's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-816.90%	-181.97%
Envoy Medical	-11,304.83%	N/A	-144.13%

Summary

Envoy Medical beats HeartSciences on 8 of the 13 factors compared between the two stocks.

How does HeartSciences compare to Nano-X Imaging?

Nano-X Imaging (NASDAQ:NNOX) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Nano-X Imaging currently has a consensus target price of $4.33, suggesting a potential upside of 574.97%. HeartSciences has a consensus target price of $8.00, suggesting a potential upside of 75.79%. Given Nano-X Imaging's stronger consensus rating and higher probable upside, equities analysts plainly believe Nano-X Imaging is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nano-X Imaging	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nano-X Imaging has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, HeartSciences has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

HeartSciences has a net margin of 0.00% compared to Nano-X Imaging's net margin of -926.05%. Nano-X Imaging's return on equity of -116.93% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nano-X Imaging	-926.05%	-116.93%	-100.67%
HeartSciences	N/A	-816.90%	-181.97%

In the previous week, HeartSciences had 3 more articles in the media than Nano-X Imaging. MarketBeat recorded 4 mentions for HeartSciences and 1 mentions for Nano-X Imaging. Nano-X Imaging's average media sentiment score of 1.05 beat HeartSciences' score of 0.97 indicating that Nano-X Imaging is being referred to more favorably in the media.

Company	Overall Sentiment
Nano-X Imaging	Positive
HeartSciences	Positive

21.5% of Nano-X Imaging shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 4.9% of HeartSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

HeartSciences has lower revenue, but higher earnings than Nano-X Imaging. HeartSciences is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nano-X Imaging	$13.02M	3.88	-$75.02M	-$2.14	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A

Summary

Nano-X Imaging beats HeartSciences on 11 of the 16 factors compared between the two stocks.

Get HeartSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HSCS vs. The Competition

Export

Metric	HeartSciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$21.85M	$5.52B	$7.31B	$12.97B
Dividend Yield	N/A	1.79%	2.52%	14.03%
P/E Ratio	-1.41	25.20	275.32	25.44
Price / Sales	N/A	71.75	661.05	107.56
Price / Cash	N/A	33.37	28.02	35.00
Price / Book	65.01	5.93	10.45	6.42
Net Income	-$9.14M	$150.75M	$3.50B	$360.15M
7 Day Performance	-2.76%	-1.03%	-1.57%	-0.74%
1 Month Performance	50.20%	-4.62%	-3.51%	-3.52%
1 Year Performance	24.68%	7.54%	14.94%	3.58%

HeartSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HSCS HeartSciences	3.216 of 5 stars	$4.55 -3.8%	$8.00 +75.8%	+29.6%	$21.85M	N/A	N/A	14	Short Interest Decrease
DXR Daxor	1.6779 of 5 stars	$11.72 +5.1%	N/A	-7.6%	$65.10M	N/A	N/A	37	Gap Up High Trading Volume
NYXH Nyxoah	3.2769 of 5 stars	$1.55 +0.6%	$4.26 +175.0%	-67.8%	$59.69M	$11.33M	N/A	154	Gap Up
OM Outset Medical	3.2405 of 5 stars	$3.12 -0.6%	$10.00 +220.5%	-79.0%	$59.02M	$119.48M	N/A	310	Positive News
COCH Envoy Medical	2.5335 of 5 stars	$0.71 +0.0%	$2.00 +181.7%	-8.3%	$54.81M	$240K	N/A	47

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HSCS) was last updated on 9/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HeartSciences (HSCS) Competitors

HSCS vs. DXR, NYXH, OM, COCH, and NNOX

How does HeartSciences compare to Daxor?

Summary

How does HeartSciences compare to Nyxoah?

Summary

How does HeartSciences compare to Outset Medical?

Summary

How does HeartSciences compare to Envoy Medical?

Summary

How does HeartSciences compare to Nano-X Imaging?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSCS vs. The Competition

HeartSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HeartSciences (HSCS) Competitors

HSCS vs. DXR, NYXH, OM, COCH, and NNOX

How does HeartSciences compare to Daxor?

Is DXR or HSCS more profitable?

Which has more risk & volatility, DXR or HSCS?

Do analysts rate DXR or HSCS?

Do institutionals and insiders have more ownership in DXR or HSCS?

Which has better valuation & earnings, DXR or HSCS?

Does the media refer more to DXR or HSCS?

Summary

How does HeartSciences compare to Nyxoah?

Is HSCS or NYXH more profitable?

Do analysts prefer HSCS or NYXH?

Does the media refer more to HSCS or NYXH?

Which has more risk & volatility, HSCS or NYXH?

Do insiders & institutionals have more ownership in HSCS or NYXH?

Which has stronger valuation and earnings, HSCS or NYXH?

Summary

How does HeartSciences compare to Outset Medical?

Do insiders and institutionals believe in OM or HSCS?

Is OM or HSCS more profitable?

Do analysts prefer OM or HSCS?

Which has more volatility & risk, OM or HSCS?

Which has stronger valuation and earnings, OM or HSCS?

Does the media favor OM or HSCS?

Summary

How does HeartSciences compare to Envoy Medical?

Does the media prefer HSCS or COCH?

Do insiders & institutionals believe in HSCS or COCH?

Which has more volatility and risk, HSCS or COCH?

Do analysts prefer HSCS or COCH?

Which has preferable earnings & valuation, HSCS or COCH?

Is HSCS or COCH more profitable?

Summary

How does HeartSciences compare to Nano-X Imaging?

Do analysts rate NNOX or HSCS?

Which has more risk and volatility, NNOX or HSCS?

Is NNOX or HSCS more profitable?

Does the media favor NNOX or HSCS?

Do institutionals & insiders believe in NNOX or HSCS?

Which has better earnings and valuation, NNOX or HSCS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSCS vs. The Competition

HeartSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools